In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...

J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its ...

Significant delays in core FDA functions — such as approving amendments to clinical trials and guiding companies through ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

Eli Lilly and Co. joined several other investors in a Series A round for a Boston biotech co-founded by the Longwood Fund that's developing a drug for a rare type of blood cancer.

In this week’s edition of InnovationRx, we look at the impact of tariffs on healthcare costs, pioneers of treating MS, AI for ...

Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.